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A study has been carried out to investigate controlled release performance of caplet shaped 26 
injection moulded (IM) amorphous solid dispersion (ASD) tablets based on the model drug 27 
AZD0837 and polyethylene oxide (PEO). The physical/chemical storage stability and release 28 
robustness of the IM tablets were characterized and compared to that of conventional extended 29 
release (ER) hydrophilic matrix tablets of the same raw materials and compositions 30 
manufactured via direct compression (DC). To gain an improved understanding of the release 31 
mechanisms, the dissolution of both the polymer and the drug were studied. Under conditions 32 
where the amount of dissolution media was limited, the controlled release ASD IM tablets 33 
demonstrated complete and synchronized release of both PEO and AZD0837 whereas the 34 
release of AZD0837 was found to be slower and incomplete from conventional direct 35 
compressed ER hydrophilic matrix tablets. The results clearly indicated that AZD0837 remained 36 
amorphous throughout the dissolution process and was maintained in a supersaturated state 37 
and hence kept stable with the aid of the polymeric carrier when released in a synchronized 38 
manner. In addition, it was found that the IM tablets were robust to variation in hydrodynamics of 39 
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1. Introduction  48 
With the advent of new manufacturing technologies and the need for increased process 49 
flexibility and efficiency, the paradigm in the pharmaceutical industry is shifting from batch to 50 
continous manufacturing. Among continuous technologies being applied to pharmaceuticals 51 
processing, hot melt extrusion (HME) technology continues to grow in importance mainly due to 52 
the advantage of being solvent-free and due to its ability to generate high density pellets that, 53 
through selection of suitable excipients, provide potential for improved stability and bioavalilabity 54 
of the finished solid oral dosage form (Breitenbach, 2002; Repka et al., 2018; Repka et al., 55 
2012). One drawback with HME, however is the need for several secondary manufacturing 56 
steps to enable a final oral solid dosage form acceptable to patients with variable needs. 57 
HME in combination with injection molding (IM) is widely used in the plastics industry to 58 
form complex shaped objects with a high degree of dimensional accuracy and reproducibility 59 
with the additional advantage of high speed (Bryce, 1996). IM has a long history in the 60 
pharmaceutical packaging and medical device field however its use as a technique for 61 
manufacturing of solid oral dosage forms was not suggested until the late 1960s (Speiser, 62 
1969). Since then, a number of techniques have been explored for producing dosage forms 63 
using small scale IM machines, with the main drivers for this research being scalability and 64 
patentability (Cuff and Raouf, 1998; Stepto and Tomka, 1987).  Additionally, manufacturing of 65 
controlled release solid oral dosage forms is possible, providing, for example, delayed release 66 
and potential targeting to colon as well as compositions preventing abuse of opioid drugs 67 
through introducing protective compartments that are resistant to destruction (Hemmingsen et 68 
al., 2011; Zema et al., 2012, Zema et al., 2013). Recently, interest in IM of pharmaceutical 69 
tablets appears to have grown, for example Eggenreich et al., 2016, compared tablets directly 70 
injection moulded from powder to those first extruded into pellets prior to moulding, and Desai et 71 
al., 2017, performed a mechanistic understanding of the effect of IM process parameters on 72 
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tablet properties. Other recent studies have explored the use of IM to produce release-73 
controlling capsule shells (Braitico-Vangosa et al., 2019), multi-compartmental capsules (Maroni 74 
et al., 2017), tablet coatings (Puri et al., 2018), sustained release tablets (Verstraete et al., 75 
2016) and a hybrid process combining 3D printing and injection moulding (Fuenmayor et al., 76 
2019). 77 
For drugs with high solubility, development of extended release (ER) hydrophilic matrix 78 
based oral solid dosage forms with predictable performance (in-vitro and in-vivo) is 79 
straightforward even at high doses (Siepmann and Peppas, 2000; Timmins et al., 2005; Larsson 80 
et al., 2008). This is due to the fact that the release of drug from the swollen matrix for highly 81 
soluble drugs is fully determined by the matrix hydration and diffusion. Developing ER 82 
hydrophilic matrix tablets based on poorly soluble drugs, on the other hand, comes with many 83 
challenges. Here, the release mechanism is primarily determined by the erosion process of the 84 
matrix and hence to a large extent by the properties of the polymeric matrix (Larsson et al. 85 
2008, Timmins et al.  2014). The result is variability in release rate throughout the gastro-86 
intestinal tract resulting from variable hydrodynamics, mechanical forces and the limited volume 87 
of GI-liquid available for dissolution. This results in both inter and intra-patient variability of 88 
performance (Grimm et al., 2017; Riethorst et al. 2018; Schiller et al., 2005; Weitschies et al., 89 
2010). As the drug content in the tablet composition increases the release will no longer be 90 
exclusively determined by the polymer characteristics, but, to an increasing extent, also by the 91 
drug characteristics such as solubility and agglomeration tendency. Knowledge of both drug and 92 
polymer release and their synchronisation is a pre-requisite to assuring robust release and to 93 
enable prediction (Abrahmsén-Alami et al., 2007; Caccavo et al., 2017; Kaunisto et al., 2011; 94 
Tajarobi et al., 2009; Tajarobi et al., 2011). For compositions with high drug content,   95 
synchronisation is not always easily achieved. Typically, the polymer release will be faster than 96 
the drug release and result in incomplete drug dissolution. In environments with low volumes of 97 
dissolution media, such as in the colon, the situation may be further exacerbated, highlighting 98 
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the need for formulations with advanced control (Amidon et al., 2015; Grimm et al., 2018; 99 
Schiller et al., 2005; Sako et al., 1993; Bar-Shalom and Kindt-Larsen, 1991, Sjökvist 1988). 100 
Here, the use of the amorphous state of a drug represents an opportunity for increased 101 
bioavailability, enabling delivery of higher and more effective doses, although, re-crystallisation 102 
or precipitation of an amorphous drug during GI-transit could still jeopardize  drug bioavailability. 103 
However, by careful selection of the polymeric carrier, the formation of amorphous solid 104 
dispersions (ASD) can assure a system with maintained performance throughout the dissolution 105 
process (Buckley et al., 2013; Wilson et al., 2018). For immediate release formulations the 106 
advantage of tailoring performance through synchronized release of polymer and drug achieved 107 
through  intimate mixing , eg ASD’s, has already been proven (Esnaashari, et al., 2005). For 108 
controlled release formulations the prerequisite of synchronized release will be even more 109 
important. Therefore, the use of IM to manufacture suitably formulated amorphous solid 110 
dispersion solid eroding oral dosage forms with controlled release performance provides an 111 
opportunity to produce robust products, optimized with regards to stability, bioavailability and 112 
patient acceptability. To our knowledge this field of reasearch has until now rarely been 113 
investigated (Pajander et al., 2017). 114 
The aim of the work was to explore how melt extruded-injection moulded ASDs can be 115 
used to produce solid dosage forms with controlled release and robust performance. In the 116 
present work, solid oral dosage forms based on amorphous solid dispersions of a poorly soluble 117 
drug (AZD0837) and polyethylene oxide were manufactured semi-continously using HME 118 
combined with IM. AZD0837 is used as a model drug in this work and was originally developed 119 
by AstraZeneca as an orally available direct thrombin inhibitor with intended use as 120 
anticoagulant therapy for the prevention and treatment of thromboembolic diseases (Olsson et 121 
al., 2010, Dunér et al., 2012). Early studies indicated that poly ethylene glycol (PEG) is a good 122 
solubilizer for AZD0837, hence, it would be expected that PEO would function as an effective 123 
ASD carrier (Unga et al., 2009). The physical/chemical storage stability and release robustness 124 
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of the tablets were characterisized and compared to that of conventional ER hydrophilic matrix 125 
tablets of the same composition. To understand the release mechanisms the dissolution of both 126 
polymer and drug were studied.  127 
The underlying hypothesis behind the approach of using ASDs manufactured by IM to 128 
gain predictable controlled drug release performance is that more intimate mixing between the 129 
components in a non-porous homogeneous matrix would assure uniform hydration and 130 
synchronized release which would reduce the likelihood of drug recrystallisation throughout 131 
dissolution - both in vitro and in vivo. 132 
 133 
2. Materials and Methods  134 
AZD0837 free base was received from AstraZeneca (Gothenburg, Sweden).  The two grades of 135 
polyethylene oxide (PEO) polymers used were kindly supplied by Dow, Polyox WSR N10 NF 136 
(1x105 g/mol) and Polyox WSR 1105 NF (9x105 g/mol). A wider range of molecular weight 137 
PEOs were initially evaluated but processability of the above grades was found to be most 138 
suited to the injection moulding process. 139 
 140 
2.1 Hot melt extrusion 141 
Blends containing AZD0837 and polyethyleneoxide (PEO) WSR were used for the HME. Two 142 
blends containing 30% (w/w) AZD0837 (with a nominal 150 mg AZD0837 tablet strength) were 143 
prepared: (i) PEO-High PM (containing 70%w/w PEO WSR1105) and (ii) PEO-Low PM 144 
(containing 20%w/w PEO WSRN10 and 50%w/w PEO WSR1105). The components required 145 
for the batch size of 500 g were weighed and mixed at 32 rpm using a shaker mixer (Shaker 146 
Mixer TURBULA® Type T2 C, Switzerland) for 8 minutes. The prepared blends were fed 147 
through a loss in weight feeder (Brabender Mini-twin, Thermo Scientific, Germany) into an 148 
intermeshing co-rotating hot melt extruder  (Pharmalab 16, Thermo Scientific, UK), using the 149 
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following temperature profile: Zone 1 = 25°C, Zone 2 = 40°C, Zone 3 = 70°C, Zone 4 to Zone 10 150 
= 130°C,  a screw rotation speed of 200 rpm and a feed rate of 0.9 kg/hr. The screw 151 
configuration (see supporting information) used for this work provided sufficient mechanical 152 
shear and residence time to yield homogeneous ASDs. Cooled extruded strands were chopped 153 
into 3 mm long cylindrical pellets using a pelletiser (Prism, Thermo Scientific, Germany). 154 
Extruder melt pressure and torque values were monitored in real time throughout the run. Those 155 
pellets are from hereon denoted PEO-High EX and PEO-Low EX, respectively. 156 
 157 
2.2 Manufacturing of IM and DC Tablets 158 
The extruded pellets of the two batches using high or low molecular weight PEO were moulded 159 
into IM tablets - from hereon denoted PEO-High IM and PEO-Low IM, respectively. Pellets were 160 
gravity fed into the IM machine (Roboshot s2000i-5a, Fanuc, Japan) fitted with a twin cavity 161 
caplet shaped mould. The optimised process parameters for IM process were as follows; 162 
injection speed: 100mm/s, pack time: 20 seconds, mould temperature: 20°C and cooling time, 163 
20 seconds. In the process the temperature, shot size and pack pressure were selected based 164 
on the rheological properties of the melt to ensure complete filling and effective packing of the 165 
material in the mould cavity. Figure 1 shows the picture of the mould cavity design and PEO-166 
High IM tablets manufactured during this work. Directly compressed ER tablets (flat-faced 167 
round, 12 mm) of the same weight and composition as IM tablets were manufactured, using a 168 
Kilian SP300 single-punch tablet press (Kilian, Germany). Those tablets are from hereon 169 
denoted PEO-High DC and PEO-Low DC, respectively. Prior to tabletting powders were 170 
weighed and mixed using a a diffusion blender (Turbula T10B/ T2F, Willy A. Bachofen Ag, 171 




2.3 Characterisation of Raw Materials, Extruded Pellets and IM Tablets  174 
2.3.1 Thermal Characterization  175 
The materials, extruded pellets and IM tablets were characterised using a TA instruments DSC 176 
Q2000 via a heat-cool-heat cycle. Samples were heated at 10C/min from 25°C to 150°C and 177 
cooled to -50°C at 10°C/min and heated again at 10°C/min to 150°C to observe thermal 178 
transitions. The IM tablets were ductile in nature thus it was possible to obtain a cross section 179 
from the middle of the tablet using a scalpel from which the sample was taken. 180 
  181 
2.3.2 Raman Spectroscopy 182 
The solid-state form of the components of the IM tablets stored at room temperature or stressed 183 
conditions (see Results and Discussion for further details) were analysed by FT-Raman 184 
spectroscopy using a MultiRAM FT-Raman Spectrometer (Bruker Optik GmbH., Ettlingen, 185 
Germany) equipped with an Nd:YAG laser excitation source operating at 1064nm. The laser 186 
was defocused at a power of 500mW. OPUS Version 7.5 (Bruker Optik GmbH, Ettlingen, 187 
Germany) was used for instrument operation and data acquisition. An average of 256 scans 188 
was obtained for each sample to obtain a good signal-to-noise ratio with a resolution of 2cm-1. 189 
AZD0837 and PEO powders were presented to the Raman spectrometer in an NMR tube and 190 
IM tablets were mounted directly on a sample holder.  191 
 192 
2.3.3 AZD0837 Content Analysis 193 
The drug content of extruded pellets and tablets was measured by dissolving approximately 500 194 
mg of pellets or tablets in 20 mL of methanol  followed by dilution with 30 mL of 0.05 M 195 
phosphate buffer pH 6.8. The resulting solutions were filtered through 0.22µm PVDF syringe 196 




2.3.4 In vitro Dissolution of AZD0837 and Polymers 199 
Dissolution testing of IM tablets was performed using USP apparatus II (at 37C using 900 mL 200 
0.05 M Phosphate buffer pH 6.8 and 50 rpm) with a paddle and a basket located at the side in 201 
the dissolution bath in a position where the sample is exposed to a laminar flow (Tajarobi et al., 202 
2009; Wingstrand et al., 1990). AZD0837 concentrations were measured with HPLC and 203 
polymer concentration was determined with SEC-MALS (Size Exclusion Chromatography 204 
coupled to Mass Spectroscopy, Wyatt Technologies, CA, USA).  Samples were collected at 205 
regular intervals up to 24 hours. At each time point 5mL samples were drawn and the same 206 
volume was replaced with phosphate buffer. 100µL of each sample was injected into the SEC 207 
system equipped with a TSKgel PWxl column (7.8 mm internal diameter × 30.0 cm length), 208 
(TOSOH Corporation, Japan). A mobile phase comprising 0.1M NaCl and 0.02% NaN3 was 209 
used for both formulations. The SEC-RI (SEC with refractive index detector) was coupled to a 210 
DAWN HELEOS II 18-angle MALS detector (Wyatt Technologies, CA, USA) and an OptilabREX 211 
refractive index detector (Wyatt Technologies, CA, USA) for concentration measurements. SEC-212 
MALS calibration was performed using Pullulan P50 (Skandinaviska Genetec AB, Mw 4.73 213 
x104, c = 0.7mg/mL in 0.1M NaCl) and polymer reference standards (in mobile phase).  Data 214 
acquisition and analysis was performed using Astra software version 6.1.7.17 (Wyatt 215 
Technologies, USA). From the concentration of polymer released at each time point and an 216 
injection volume of 100 µL, concentration and cumulative % polymer release was calculated.  217 
 218 
2.3.5 Stressed Stability Study 219 
The stability performance of IM tablets stored at room temperature (RT) for more than 1 year 220 
and for tablets stored under stressed conditions (at 40°C and 75% RH (open) for 19 days) were 221 
determined through analysis of drug content, weight, physical form and dissolution performance. 222 
For comparison, an analogous study was made for the extruded pellets and IM tablets under 223 
ambient condition (RT) within three days after manufacturing. 224 
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3. Results and Discussion 225 
3.1 Material Properties of Raw Materials 226 
The melting point and associated melting enthalpy of pure materials as received from the 227 
supplier and their physical mixtures were determined and are presented in Table 1. PEO 228 
exhibits a sub-0oC glass transition temperature (Tg) and melts in the region of 66-70C (Abu-229 
Diak et al., 2012; Pajander et al., 2017). Thermal analysis of AZD0837 using DSC showed a 230 
melting endotherm at 117.8°C indicating the crystalline nature of the drug substance. The two 231 
grades of PEO showed melting endotherms in the range of 66.0 to 69.0°C indicative of the 232 
semi-crystalline nature of the PEO (Zhao et al., 2005). The suitability of the drug substance to 233 
form an ASD was also considered via the concept of the glass forming ability (GFA) and Glass 234 
stability (GS) as proposed by Baird (Baird et al., 2010).  GFA of the material is defined as the 235 
ability of substances to vitrify on cooling from the melt. GFA accounts for the ease of vitrification 236 
of a liquid/melt upon cooling whereas GS accounts for the resistance of a glass towards 237 
devitrification upon heating (Baird et al., 2010). One of parameter often used to assess the GFA 238 
of organic molecules is the reduced glass transition temperature (Trg) which was first described 239 
by Kauzmann (Kauzmann, 1948) and later proposed by Turnbull (Turnbull, 1969) equation 1: 240 
𝑇𝑟𝑔 =   𝑇𝑔 𝑇𝑚⁄                       (1) 241 
Where Tg is the glass transition temperature and Tm is the melting temperature. Assuming that 242 
viscosity is constant at Tg, materials with higher Trg values would be expected to have a higher 243 
viscosity between Tg and Tm and consequently be more resistant to crystallization (Baird et al., 244 
2010). Thus, the closer the Trg value is to 1, the higher the material’s GFA. When the 245 
classification system is applied to assess the crystallisation tendency of AZD0837 two distinct 246 
observations were made. Firstly, its Trg was found to be 0.8 suggesting that the drug substance 247 
has an excellent GFA, and, secondly, it belongs to class III i.e. no crystallisation was observed 248 
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upon either cooling from a completely molten state to below Tg or upon subsequent reheating to 249 
the melting point (see Figure S1 in supporting information). Therefore it is well suited to 250 
amorphous solid dispersion formation.  251 
Thermal data, the melting enthalpies in particular, obtained from the analysis of the raw 252 
materials on their own as well as in the physical mixtures were studied in conjunction with PEO 253 
molecular weights. In Table 1 the estimated crystallinity of PEO grades is reported. It was found 254 
that PEO WSR N10 and PEO WSR 1105 exhibited crystallinities of 88.5% and 86.9% 255 
respectively, corresponding to amorphous contents of 11.5% and 13.1% respectively. This is 256 
consistent with the well-known semi-crystalline nature of PEO (Bogdanov, B. and M. Mihailov , 257 
1985).   258 
 259 
The melting enthalpy (ΔH) of drug substance in the PEO-High PM and PEO-Low PM was found 260 
to be 9.1 Jg-1 and 1.5 Jg-1 respectively, which represent significant differences to the melt 261 
enthalpy of pure AZD0837 (89.6 Jg-1). These results suggest some crystalline content was still 262 
present in the mixture after the first heating. However, the greater decrease in melting enthalpy 263 
(ΔH) of AZD0837 observed in the case of PEO-Low PM suggests that AZD0837 to a larger 264 
extent has been solubilised in the PEO above its melting point and remains solubilized (in the 265 
amorphous regions of the polymer) upon cooling (Trotzig et al., 2007; Unga et al., 2009). 266 
Furthermore, a melting point depression from 117.8C for pure AZD0837 to 113.2C was also 267 
observed for the PEO-Low PM. This decrease in the melting point of AZD0837 is  indicative of 268 
greater miscibility and solubility of AZD0837 in PEO-Low PM than in PEO of high molecular 269 
weight, where the drug melting point reduced only to 116.5oC (Table 1) (Deshmukh, 2015; 270 
Marsac et al., 2006). The % crystallinity of PEO in the physical mixture was observed to be 271 
87.7% and 92.5% for PEO-High PM and PEO-Low PM respectively which suggests PEO 272 
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crystallinity in the physical mixture does not significantly change and exhibits similar % 273 
crystallinity when compared to the pure PEO polymers. 274 
  275 
3.2 Manufacturing using HME and IM  276 
IM is a cyclic process in which molten material is injected into a mould cavity under pressure 277 
where it is solidified into a final shape. The process consists of five phases: (i) mould clamping; 278 
(ii) injection; (iii) packing; (iv) cooling and plasticisation; (v) mould opening and part ejection. 279 
During an injection phase, molten material is injected into the mould cavity at a controlled speed 280 
by lateral movement of the screw. A constant pressure is then applied by the screw during the 281 
packing phase to allow additional material to flow into the mould cavity during cooling and 282 
solidification. This avoids formation of shrinkage marks and voids. Following a sufficient period 283 
of cooling, the screw is then rotated and forced backwards to prepare the next shot of the 284 
molten material, termed plasticisation. Finally, the mould halves open and the solidified parts 285 
are ejected by sliding pins.  286 
The HME process variables such as melt temperature, feed rate, screw speed and screw 287 
configuration are known to have a possible effect on the homogeneity and quality of ASDs 288 
(Repka et al., 2018; Repka et al., 2012). The screw configuration used for this work was kept 289 
constant for both the formulations and the other process variables were optimised to obtain 290 
homogenous ASDs (see Figure S2 and Table S1 in supporting information). The plasticisation 291 
effect of PEO on the drug leads to increased molecular mobility and decreased viscosity of the 292 
drug-polymer melt compared to the pure polymer system. During HME, the steady state torque 293 
for PEO-High and PEO-Low was observed to be 6.32 Nm and 5.36 Nm, respectively, which 294 
indicates, as expected, that the PEO-Low EX system exhibits a lower melt viscosity than PEO-295 
High EX system, which can be attributed to the difference in PEO molecular weights. Likewise, 296 
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the melt pressure was observed to be 28 bar and 22 bar respectively for PEO-High and PEO-297 
Low suggesting a lower viscosity of PEO-Low melt than the PEO-High. 298 
The volume of melt required to form a satisfactory moulded component is termed as the shot 299 
size, which is set by in the initial position of the screw. In this study, mould cavity filling was 300 
optimised by increasing the shot size in increments of 1 mm, as shown for PEO-High IM tablet 301 
in Figure 2.  Incomplete filling and inadequate packing of moulded part leads to warping, 302 
formation of sink marks and shrinkage, whereas higher pack pressure and packing time can 303 
result in an increase part weight due to densification.  As shown in Figure 2, a shot size of 16 304 
mm was sufficient to fill the mould cavity, however a small amount of pack pressure (300 bar) 305 
was essential to produce a fully formed and acceptable IM product.  306 
 307 
 308 
3.3 Thermal and Raman Analysis of IM Tablets  309 
The Figure 3A shows that pure crystalline AZD0837 displayed a melting endotherm at 117.8C 310 
but no melting endotherm was observed in either melt extruded or moulded systems, confirming 311 
the formation of ASDs in all cases. The melting enthalpies of the PEO obtained in the physical 312 
mixture (Table 1) were compared with enthalpies of the melt extruded and IM tablets (Table 2) 313 
and a reduction in the melting enthalpy to approximately 50% was observed. This reduction is 314 
also associated with a reduction in the crystallinity of PEO-Low EX and PEO-High EX to 46.1% 315 
and 45.9%, respectively, after extrusion. When taking the effect of AZD0837 into account, the 316 
melting enthalpy and degree of crystallinity of PEO-Low HME and PEO-High HME correspond 317 
well to that previously reported for meltprocessed PEO WSR N10 (Trotzig et al., 2007).  No 318 
further reduction of melting enthalpy and melting temperature was observed though, after 319 
injection moulding. Hence, PEO in these systems is to a higher degree amorphous which 320 




Raman spectra of the injection moulded solid dispersions were compared to that of the raw 323 
materials (Figure 3B). Data is presented to reflect the fingerprint region. Peaks at 327 cm-1 and 324 
256 cm-1 are characteristic of crystalline AZD0837 and their absences in both solid dispersion 325 
formulations clearly indicate amorphization of the drug and it complements the obtained DSC 326 
data. These peaks were well resolved from PEO peaks at 363 and 279 cm-1 (Figure 3B, C-F) 327 
and were therefore chosen to identify the presence of crystalline AZD0837 in a region without 328 
interfering peaks from raw materials. One consideration is that backscattering Raman 329 
measurements constitute a surface analysis of the region of the IM tablets in the laser path. 330 
Hence, Raman will not provide information about drug form in the bulk of the tablet. However, 331 
absence of crystallinity in the bulk of both PEO-High IM and PEO-Low IM tablets measured by 332 
DSC is consistent with complete amorphization of the drug as do the release studies discussed 333 
further below (Figure 3A).  334 
3.4 Release Performance of IM and DC Tablets 335 
The in-vitro dissolution of AZD0837 (30% w/w) from IM tablets with polyethylene oxide (PEO) as 336 
a matrix-former is shown in Figure 4. Complete release of AZD0837 occurred after 7 to 8 hours. 337 
The polymer and drug release are clearly shown to be synchronized for both compositions 338 
studied. Even though the PEO-Low IM composition contains a significant amount of low 339 
molecular weight PEO (20% w/w PEO WSRN10) the release of drug and polymer is not 340 
dramatically faster than that of PEO-High IM. The time to 50% release only decreased from 3.2 341 
to 2.9 hours, hence, the effect of increased polymer molecular weight on the release is relatively 342 
small in this case (see Table 3). Another important observation to highlight here is that the full 343 
dose (nominally 150 mg) is released into the dissolution media (900 mL). This corresponds to a 344 
drug concentration of 0.17 mg/ml in the bath at the end of the experiment which is close to the 345 
solubility limit of the pure crystalline drug (S0 = 0.2 mg/mL) indicating that AZD0837 most 346 
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probably remains in an amorphous state throughout the dissolution process even though sink 347 
conditions are not met. The drug release was also studied for hot melt extruded pellets prior to 348 
injection moulding (Figure S3 in Supporting Information). Drug release was found to be faster 349 
for extruded pellet formulations compared to that of moulded tablets.  This is thought to result 350 
from a combined effect of the larger surface area available for release from pellets and the 351 
possible densification of the composition resulting from higher pressures experienced in the 352 
moulding process which would be expected to retard water uptake and subsequent drug 353 
dissolution.  354 
Direct compressed (DC) compositions containing 30% (w/w) crystalline AZD0837 with the same 355 
nominal drug dose (150 mg) were manufactured for comparison with the IM tablets. In Figure 4 356 
A & B the dissolution results are plotted together with the corresponding data from the IM tablets 357 
using the non-sink dissolution test described above for IM tablets. Significant differences 358 
between the two systems are clearly evidenced (Figure 4 and Table 3). Unlike the IM tablets 359 
where the drug and polymer release are well synchronized, the drug and polymer release 360 
profiles from the DC tablet are poorly synchronized and both drug and polymer dissolution are 361 
significantly slower than that of the IM tablets. Also note that the difference in release of PEO 362 
between PEO-High and PEO-Low is greater for the DC tablets than for IM tablets (T50 ratio 1.4 363 
compared to 1.1), Table 3, which is discussed further below. A further observation from the data 364 
presented in Figure 4 is that the drug release for DC tablets is incomplete at the end of the test 365 
whereas the polymer is released fully. These results are in line with those from a previous study 366 
where high dose PEO based IM tablets with carbamazepine in crystalline form did not release 367 
the full drug dose (Pajander et al., 2017). Note specifically that the drug release starts to plateau 368 
at the point where 100 % of the polymer is released (10 and 15 h for PEO-low DC and PEO-369 
High DC, respectively), hence after this point the pure drug characteristics fully determines the 370 
release rate. Due to the immediate faster onset of polymer release observed, as the dissolution 371 
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process proceeds, the drug release rate becomes, increasingly limited by the reduced matrix 372 
hydration rate, caused by the increased concentration of the low solubility crystalline drug in the 373 
remaining matrix. Hence the full dose cannot be released under the test conditions used, in 374 
which true sink conditions is not fully achieved. Interestingly, such behaviour is not observed 375 
under sink conditions as exemplified by the study of Tajarobi  (Tajarobi et al., 2011). In that 376 
study, drug release was complete for crystalline poorly soluble drugs, and, the difference in 377 
release behaviour between physical mixtures containing a poorly soluble crystalline drug and 378 
solid dispersions with drug in amorphous form of the same PEO-containing compositions, was 379 
minor.  380 
 381 
Figure 5 shows polymer and drug release of the PEO-High IM tablets at varying stirring rate. 382 
Upon an increase of stirring rate from 50 to 100 rpm a decrease of the time to 50% released is 383 
observed (from approximately 2.9 h to 2.4 h giving a T50 ratio of approximately 1.2). The data 384 
indicates that the release of poorly soluble drugs formulated as a controlled release amorphous 385 
solid dispersion using injection moulding has a release less susceptible to variation in 386 
hydrodynamics than ER matrix compositions of poorly soluble drugs made using conventional 387 
manufacturing methods with similar polymers including dry powder mixing or granulation before 388 
final tabletting (Abrahmsén-Alami et al., 2007; Körner et al., 2005; Wang et al., 2017). However, 389 
further studies including direct comparisons would be needed to understand the difference in 390 
performance in detail.  It is important to note that the polymer and drug release are well 391 
synchronized also at the high stirring rate even though the amount of dissolution media was 392 
lower in this study (500 mL). In this case, complete dissolution of the drug dose corresponds to 393 
a concentration in excess of the crystalline drug solubility and the system will become 394 
supersaturated. The observation that complete drug release is observed from the IM tablets 395 
under these conditions suggests that drug crystallization is insignificant and that the drug is 396 
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maintained in an amorphous state throughout the dissolution process. The ability of the IM 397 
tablets to achieve comparable dissolution performance under different dissolution regimes with 398 
respect to hydrodynamics and volume points to a high release robustness of IM tablets. 399 
 400 
3.5 Stressed Stability of IM Tablets 401 
The stability performance of IM tablets stored at room temperature (RT) and 20% relative 402 
humidity (RH) for more than 1 year and for tablets stored under stressed conditions, 40°C and 403 
75% RH (open) for 19 days, were determined through analysis of drug content, weight, physical 404 
form and dissolution performance. It was found that IM tablets took up water to varying extents 405 
after storage at RT and under stressed conditions (Table 4). Surprisingly, the PEO-High IM 406 
tablets, in spite of the high polymer hydrophilicity, did not absorb moisture to any measurable 407 
amount during storage at RT and low RH. Even under stressed conditions these tablets took up 408 
only a small amount of water (~3% w/w). The tablets containing PEO of low molecular weight 409 
(PEO-Low) on the other hand absorbed significantly more water at RT and under stressed 410 
storage (>10%). In spite of this AZD0837 remained chemically stable during long-term RT 411 
storage both in PEO-Low and PEO-High IM tablets (loss of assay < 0.2% for PEO-High and < 412 
2% for PEO-Low). 413 
 To investigate stability against recrystallization during storage, the solid-state form of 414 
AZD0837 in IM tablets was probed by Raman spectroscopy after stressed storage and 415 
compared to that of IM tablets stored at RT (> 1 year) (Figure 6). In the formulation containing 416 
only high molecular weight PEO, no recrystallization was evident after storage (Figures 6A and 417 
6B).  In contrast, the formulation containing both high and low MW PEO revealed minor 418 
recrystallisation on storage as shown by crystalline AZD0837 peaks at 327 cm-1 and 256 cm-1 419 
(Figure 6E). This finding corresponds to the higher uptake of water of the formulation containing 420 
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low molecular weight PEO (Table 3). Water will act both as an anti-solvent for the poorly soluble 421 
AZD0837 and facilitate crystallisation of the drug via plasticisation of regions of amorphous PEO 422 
polymer (Trotzig et al., 2007). Re-crystallisation of amorphous PEO in the presence of water 423 
with the exclusion of solubilised drug is a further mechanism to promote drug crystallisation. 424 
Nonetheless, the presence of crystalline drug did not influence drug release, as shown in Figure 425 
7. It should be noted however that Raman analysis is sensitive only to a small region of the 426 
tablet surface, indicating that the crystallinity observed could be a very minor when compared to 427 
total AZD0837 content of the IM tablets. 428 
 The recrystallization tendency of AZD0837 was also investigated upon hydration of the IM 429 
tablets by submerging them in 100 mL of water for 30 minutes prior to analysis (Figures 6C and 430 
6F). Interestingly, crystalline AZD0837 peaks that were present at the surface of the dry IM 431 
tablet containing low molecular weight PEO were no longer present upon hydration (Figure 6, 432 
spectra F) suggesting release of crystalline AZD0837 initially present at the tablet surface into 433 
the surrounding medium or that crystallites were not present at the specific surface position 434 
probed either before or after hydration.   435 
Data on the recrystallization tendency of AZD0837 during storage and wetting revealed 436 
that these polymeric carriers in an IM tablet were to a large extent effective in stabilising the 437 
drug in an amorphous form during storage and upon hydration.To assure adequate 438 
performance AZD0837 dissolution after storage at RT (> 1 year) and after stressed storage was 439 
compared. The most important observation from this study is that the dissolution of AZD0837 440 
did not change significantly after storage under stressed conditions (Figure 7). Only a very slight 441 
increase in release rate is observed for both drug and polymer (very close to the variability of 442 
the methodology), as shown in Table 3 and Figure 7.  Alternatively, polymer degradation during 443 
stressed storage could be suggested. However, previous work using similar process conditions 444 
indicate that the polymer molecular weight should not be substantially affected by the process 445 
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(Pajander et al., 2017). Note here also that only 500 mL dissolution media was used for 446 
dissolution testing, indicating, again, that full and robust release is assured even under non-sink 447 
conditions also after the IM tablets had experienced a severe challenge with respect to 448 
temperature and humidity. 449 
 450 
3.6 Considerations for Robust Release Performance 451 
 The present study indicates that by formulating controlled release oral solid dosage forms 452 
using IM combined with formation of ASD’s provide opportunities for drug products with robust 453 
release characteristics. Specifically, it is shown that the release profile and rate of release is 454 
maintained under variable conditions and after stressed storage. The results of this study 455 
indicate that AZD0837 in IM tablets is maintained in an amorphous solid state throughout the 456 
dissolution process, and, with the aid of the polymeric carriers (here PEO), also achieves 457 
supersaturated concentrations (Bevernage et al., 2013; Saboo et al., 2019). An enabler for the 458 
stabilisation in the swollen matrix tablet and in solution is that the polymer and drug release are 459 
synchronized throughout the dissolution process. Previous studies have shown similar and 460 
synchronized release (polymer/drug) for PEO/PEG based DC tablets containing drugs with 461 
relatively low aqueous solubility (butyl-parabens) in both physical mixtures and ASD’s when 462 
under sink-conditions (Tajarobi et al., 2011).  However, the current study shows that it is not 463 
possible to achieve synchronized release between polymer and drug under non-sink conditions 464 
for physically mixed DC tablets with the drug in its crystalline form. The reason for this behavior 465 
is that upon hydration water enters the matrix via hydrophilic polymer channels and the polymer 466 
starts to dissolve and translate through the matrix. This highlights the superior robustness of IM 467 
tablets compared to physical mixtures in that the formation of an ASD assures intimate mixing 468 
and absence of these channels. 469 
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 In general, for physically mixed direct compressed ER matrix systems where the release 470 
rate is determined mainly by the erosion of the polymer matrix, a large variation in release rate 471 
is observed when the polymer molecular weight is varied (Siepmann and Peppas, 2000). The 472 
results for ASD IM tablets in the current work does not show a large variability with molecular 473 
weight of the polymer. This diverges somewhat from results presented in the literature for matrix 474 
tablets based on direct compressed physical mixtures of PEO of various molecular weights with 475 
and without poorly soluble model drugs (Abrahmsén-Alami et al., 2007; Körner et al., 2005; 476 
Maggi et al., 2002). The larger effect of polymer molecular weight on release from DC tablets of 477 
the current study, however, corresponds well to historical observations. Furthermore, a recently 478 
published study reported that for IM tablets with crystalline drugs, an effect of the molecular 479 
weight of the PEO on the drug release is observed (Pajander et al., 2017). Hence, the reduced 480 
effect of the polymer molecular weight on IM tablets of the present study appears to be related 481 
to the formation of an ASD and that the polymer dissolution process is influenced by the 482 
hydrophobic drug. Consequently, the release for IM tablets will to a larger extent be determined 483 
by the hydration rate of the matrix (Tajarobi et al., 2011; Bar-Shalom and Kindt-Larsen 1991). 484 
To clarify further, for ASD’s the dissolution mechanism of both polymer and drug substance is 485 
determined by characteristics of the combined system. As the content of poorly soluble or 486 
sparingly soluble drug in the system increases, the rate of hydration will decrease, for both 487 
physical mixtures and ASD’s but the intimate mixing between the components in ASD’s assure 488 
uniform hydration and synchronized dissolution of polymer and drug. 489 
 The present work highlights the advantages of controlled release ASD IM tablets in that they 490 
provide release characteristics that are more robust to several parameters of importance for in-491 
vivo performance. The compositions described in this study were proved to maintain the drug in 492 
its amorphous state throughout the full dissolution process also under conditions where the 493 
amount of fluid amount available to dissolve the drug was limited (Grimm et al., 2018). In future 494 
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studies of these systems it would be important to consider alternative dissolution methodologies 495 
to gain a better understanding of the in-vivo behaviour and potential additional advantages 496 
compared to tablets manufactured by direct compression (Abrahmsén-Alami et al., 2007 S., 497 
Körner, A., Nilsson, I., Larsson, A., 2007, Andreas et al., 2018; Butler et al., 2019; Kostewicz et 498 
al., 2014).  499 
4. Conclusion  500 
 Melt extrusion combined with injection moulding was found to be an effective methodology 501 
to produce controlled release ASD dosage forms with robust performance. A twin-cavity caplet 502 
shaped mould was successfully used to produce moulded amorphous solid dispersions of 503 
AZD0837 within a PEO matrix. The melt viscosity-lowering effect of AZD0837 on PEO was 504 
found to be beneficial for mould filling during injection, resulting in dense controlled release ASD 505 
IM tablets where AZD0837 was effectively maintained in an amorphous state under various 506 
storage conditions and throughout the complete release duration (8-12 hours). When compared 507 
to conventional directly compressed ER hydrophilic matrix tablets of the same composition, 508 
controlled release IM ASD tablets were found to exhibit superior dissolution performance. 509 
Results indicated that AZD0837 in IM tablets remained amorphous throughout the dissolution 510 
process and was maintained in a supersaturated state and hence kept stable with the aid of the 511 
polymeric carrier which was shown to be released in a synchronized manner. For ER DC 512 
tablets, AZD0837 release was slower and incomplete due to poor synchronization with the 513 
polymer release. IM ASD tablets were also significantly more robust to variation in 514 
hydrodynamics of the dissolution environment and PEO molecular weight. Controlled release 515 
ASD tablets manufactured via HME-IM offer potential to be integrated into a continuous large-516 
scale manufacturing line to achieve predictable controlled release of poorly soluble drugs 517 
throughout the gastrointestinal tract. 518 
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